Abstract #0186

Ferumoxytol-enhanced Pulmonary MRA in Pregnancy: Evaluation of Initial Safety and Image Quality

Jitka Starekova¹, Scott K Nagle¹, Mark L Schiebler¹, Scott B Reeder^1,2,3,4,5, and Venkata N Meduri¹

¹Radiology, University of Wisconsin-Madison, Madison, WI, United States, ²Medicine, University of Wisconsin-Madison, Madison, WI, United States, ³Medical Physics, University of Wisconsin-Madison, Madison, WI, United States, ⁴Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, United States, ⁵Emergency Medicine, University of Wisconsin-Madison, Madison, WI, United States

Ferumoxytol (Feraheme®, AMAG Pharmaceuticals, Waltham) is an injectable iron micro particle-solution approved by the FDA for treatment of iron-deficiency anemia. This medication also has favorable properties as intravascular blood pool agent (off-label) for contrast-enhanced MRA (Fe-MRA). Fe-MRA is an alternative modality for the assessment of pulmonary embolism without the need for ionizing radiation or gadolinium in pregnant patients. The purpose of this study was to summarize our clinical experience with 70 Fe-MRA exams in 66 pregnant patients. We aimed to demonstrate the safety and efficacy of Fe-MRA and provide guidance in establishing a clinical service.

This abstract and the presentation materials are available to members only; a login is required.

Join Here